Trial Profile

Phase III Double-blind Randomized Placebo Controlled Trial of Atezolizumab in Combination With Paclitaxel and Carboplatin in Women With Advanced/Recurrent Endometrial Cancer

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 16 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Atezolizumab (Primary) ; Carboplatin; Paclitaxel
Indications Adenocarcinoma; Carcinoma; Endometrial cancer; Sarcoma
Focus Therapeutic Use
Acronyms AtTEnd; AtTEnd/ENGOT-en7

Most Recent Events

09 May 2025 Status changed from active, no longer recruiting to completed.
11 Mar 2024 Planned primary completion date changed from 1 Nov 2023 to 1 Jan 2025.
24 Oct 2023 Primary endpoint has been met. (PFS in the MSI [ Time Frame: Up to 18 months after the last patient enrolled ]) , according to Results presented at the 48th European Society for Medical Oncology Congress

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com